Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus NEUROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus NEUROLITE.
INDIUM IN 111 OXYQUINOLINE vs NEUROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
NEUROLITE is a sodium channel blocker that stabilizes neuronal membranes and inhibits the release of excitatory neurotransmitters, thereby reducing neuronal excitability and seizure propagation.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal half-life: 12-15 hours; steady-state reached in 2-3 days
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Renal: 70% unchanged; Biliary/Fecal: 15% as metabolites; 15% other
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical